Citations (28)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Ning Shao, Hong Tang, Yuanyuan Mi, Yao Zhu, Fangning Wan & Dingwei Ye. (2020) A novel gene signature to predict immune infiltration and outcome in patients with prostate cancer. OncoImmunology 9:1.
Read now
Read now
Sumanta K. Pal, Eric Jonasch, James E. Signorovitch, William M. Reichmann, Nanxin Li, Zhimei Liu, Jose Ricardo Perez & Nicholas J. Vogelzang. (2016) Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the US. Journal of Medical Economics 19:5, pages 462-468.
Read now
Read now
Jens Bedke, Stephan Kruck, Georgios Gakis, Arnulf Stenzl & Peter J Goebell. (2015) Checkpoint modulation - A new way to direct the immune system against renal cell carcinoma . Human Vaccines & Immunotherapeutics 11:5, pages 1201-1208.
Read now
Read now
Jens Bedke & Arnulf Stenzl. (2013) Immunotherapeutic strategies for the treatment of renal cell carcinoma: where are we now?. Expert Review of Anticancer Therapy 13:12, pages 1399-1408.
Read now
Read now
Jens Bedke & Arnulf Stenzl. (2013)
IMA901: a peptide vaccine in renal cell carcinoma. Expert Opinion on Investigational Drugs 22:10, pages 1329-1336.
Read now
Read now
Jens Bedke, Cécile Gouttefangeas, Stephan Kruck & Arnulf Stenzl. (2012) A vaccine in renal cell carcinoma: are we nearing reality?. Expert Review of Anticancer Therapy 12:12, pages 1503-1505.
Read now
Read now
Articles from other publishers (22)
Yanting Shen, Huan Xu, Manmei Long, Miaomiao Guo, Peizhang Li, Ming Zhan & Zhong Wang. (2021) Screening to Identify an Immune Landscape-Based Prognostic Predictor and Therapeutic Target for Prostate Cancer. Frontiers in Oncology 11.
Crossref
Crossref
Xinji Zhang, Xiaojun Shi, Jinlong Li, Zhiming Hu, Jimin Gao, Shihao Wu & Zhaolin Long. (2019) Combination immunotherapy with interleukin-2 surface-modified tumor cell vaccine and programmed death receptor-1 blockade against renal cell carcinoma. Cancer Science 110:1, pages 31-39.
Crossref
Crossref
Viktoria Stühler & Jens Bedke. (2018) Das NierenzellkarzinomOverview of treatment of localized and metastatic renal cell carcinoma (RCC). MMW - Fortschritte der Medizin 160:8, pages 45-51.
Crossref
Crossref
Michael Reiter, Ines Eckhardt, Axel Haferkamp & Simone Fulda. (2016) Smac mimetic sensitizes renal cell carcinoma cells to interferon-α-induced apoptosis. Cancer Letters 375:1, pages 1-8.
Crossref
Crossref
Josiah D Land, Adrienne H Chen, Bradley J Atkinson, Diana H Cauley & Nizar M Tannir. (2014) Proteinuria with first-line therapy of metastatic renal cell cancer. Journal of Oncology Pharmacy Practice 22:2, pages 235-241.
Crossref
Crossref
Jens Bedke & Arnulf Stenzl. (2016) Re: Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. European Urology 69:3, pages 538-539.
Crossref
Crossref
Axel Merseburger, Mohammad Kabbani & Christoph von Klot. 2016. Die Urologie. Die Urologie
387
394
.
Amancio Carnero, Carmen Blanco-Aparicio, Hiroshi Kondoh, Matilde E. Lleonart, Juan Fernando Martinez-Leal, Chiara Mondello, A.Ivana Scovassi, William H. Bisson, Amedeo Amedei, Rabindra Roy, Jordan Woodrick, Annamaria Colacci, Monica Vaccari, Jayadev Raju, Fahd Al-Mulla, Rabeah Al-Temaimi, Hosni K. Salem, Lorenzo Memeo, Stefano Forte, Neetu Singh, Roslida A. Hamid, Elizabeth P. Ryan, Dustin G. Brown, John Pierce WiseSrSr, Sandra S. Wise & Hemad Yasaei. (2015) Disruptive chemicals, senescence and immortality. Carcinogenesis 36:Suppl 1, pages S19-S37.
Crossref
Crossref
Antoine Thiery-Vuillemin, Christine Theodore, Lutz Jacobasch, Jörg Schmitz, Christos Papandreou, Aline Guillot, Christos Emmanouilides, Khemaies Slimane, Nadia Kelkouli, Stefano Kim & Thierry Nguyen Tan Hon. (2015) Efficacy and Safety of Sequential Use of Everolimus in Patients With Metastatic Renal Cell Carcinoma Previously Treated With Bevacizumab With or Without Interferon Therapy: Results From the European AVATOR Study. Clinical Genitourinary Cancer 13:3, pages 231-238.
Crossref
Crossref
Axel S. Merseburger, Mohammad Kabbani & Christoph A. von Klot. 2015. Die Urologie. Die Urologie
1
10
.
Walid Zaher & Moustapha Kassem. 2015. Somatic Genome Manipulation. Somatic Genome Manipulation
105
121
.
Steffen Rausch, Stephan Kruck, Arnulf Stenzl & Jens Bedke. (2014) IMA901 for metastatic renal cell carcinoma in the context of new approaches to immunotherapy. Future Oncology 10:6, pages 937-948.
Crossref
Crossref
Jens Bedke & Peter J. Goebell. (2014) Im Fokus — das Nierenzellkarzinom. Info Onkologie 17:4, pages 23-26.
Crossref
Crossref
Giuseppe Di Lorenzo & Sabino De Placido. (2014) Using cumulative toxicity to identify the optimal second-line targeted therapy in patients with metastatic renal cell carcinoma: what’s new?. Future Oncology 10:5, pages 845-850.
Crossref
Crossref
Lin Fang, Qian Cheng, Wang Li, Junjie Liu, Liantao Li, Kai Xu & Junnian Zheng. (2014) Antitumor activities of an oncolytic adenovirus equipped with a double siRNA targeting Ki67 and hTERT in renal cancer cells. Virus Research 181, pages 61-71.
Crossref
Crossref
Stephan Kruck, Axel S. Merseburger, Arnulf Stenzl & Jens Bedke. (2013) How far is the horizon? From current targets to future drugs in advanced renal cancer. World Journal of Urology 32:1, pages 69-77.
Crossref
Crossref
Jens Bedke, Cécile Gouttefangeas, Harpreet Singh-Jasuja, Stefan Stevanović, Carl-Ludwig Behnes & Arnulf Stenzl. (2013) Targeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapy. World Journal of Urology 32:1, pages 31-38.
Crossref
Crossref
Alessio Lanna, Elias Coutavas, Lauretta Levati, Judith Seidel, Malcolm H. A. Rustin, Sian M. Henson, Arne N. Akbar & Ornella Franzese. (2013) IFN-α Inhibits Telomerase in Human CD8+ T Cells by Both hTERT Downregulation and Induction of p38 MAPK Signaling. The Journal of Immunology 191:7, pages 3744-3752.
Crossref
Crossref
Stephan Kruck, Marcus Scharpf, Arnulf Stenzl & Jens Bedke. (2013) A Rare Case of Synchronous Renal Cell Carcinoma of the Bladder Presenting with Gross Hematuria. Rare Tumors 5:2, pages 72-74.
Crossref
Crossref
Stephan Kruck, Christian Eyrich, Marcus Scharpf, Karl-Dietrich Sievert, Falco Fend, Arnulf Stenzl & Jens Bedke. (2013) Impact of an Altered Wnt1/β-Catenin Expression on Clinicopathology and Prognosis in Clear Cell Renal Cell Carcinoma. International Journal of Molecular Sciences 14:6, pages 10944-10957.
Crossref
Crossref
George J. Netto. (2013) Clinical Applications of Recent Molecular Advances in Urologic Malignancies. Advances in Anatomic Pathology 20:3, pages 175-203.
Crossref
Crossref
Jens Bedke, Felix K.‐H. Chun, Axel Merseburger, Marcus Scharpf, Kathrin Kasprzyk, David Schilling, Karl‐Dietrich Sievert, Arnulf Stenzl & Stephan Kruck. (2012)
Inflammatory prognostic markers in clear cell renal cell carcinoma – preoperative
C
‐reactive protein does not improve predictive accuracy
. BJU International 110:11b.
Crossref
Crossref